Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Gregory Dale Kirk, M.D., M.P.H., Ph.D.
Joint Appointment in Oncology
Expertise: Epidemiology, Hepatitis, HIV/AIDS, Infectious Disease
Research Interests: Hepatitis B virus; Hepatitis C virus; HIV/AIDS; HAART; Non-AIDS outcomes (lung, liver disease); Drug use; Epidemiology; Liver cancer; Biomarkers; Proteomics; Genetic susceptibility; ALIVE study; The Gambia; Uganda ...read more
Request an Appointment
I live in Maryland
Request an appointment through My
I live outside of Maryland
I live outside of the United States
Johns Hopkins Bayview Medical Center
Appointment Phone: 410-955-1725
4940 Eastern Avenue
Baltimore, MD 21224 map
The Johns Hopkins Hospital
Appointment Phone: 410-955-1725
600 N. Wolfe Street
Sheikh Zayed Tower
Baltimore, MD 21287 map
Dr. Gregory Kirk is a professor of medicine at the Johns Hopkins University School of Medicine. He holds joint appointments in oncology and, at the Johns Hopkins Bloomberg School of Public Health, in epidemiology. His areas of clinical expertise include epidemiology, hepatitis, HIV, AIDS and infectious diseases.
He serves as the vice chair for clinical and translational research at the Johns Hopkins School of Medicine.
Dr. Kirk received his undergraduate degree from Oklahoma State University. He earned a Ph.D. and M.P.H. from the Johns Hopkins Bloomberg School of Public Health. He earned his M.D. from the University of Oklahoma Health Sciences Center College of Medicine. He completed a residency in preventative medicine at the Johns Hopkins Bloomberg School of Public Health and in internal medicine at Georgetown University. He performed a fellowship in infectious diseases at the National Institute of Allergy and Infectious Diseases.
His research focuses on understanding and preventing the long-term consequences of chronic HIV infection, particularly the malignant complications of HIV and viral hepatitis. He has extensive research and clinical experience in Africa, leading the Gambia Liver Cancer Study, one of the largest studies of hepatocellular carcinoma (HCC) performed in the continent, in addition to years of collaborative research in Uganda.
Dr. Kirk pioneered the use of elastography and application of novel aflatoxin-associated biomarkers of HCC risk to be applied in Consortium projects. He has strong, multidisciplinary team leadership skills as principal investigator of the ALIVE cohort and several other collaborative studies in Baltimore.
- Joint Appointment in Oncology
- Professor of Medicine
- MD, University of Oklahoma Health Sciences Center College of Medicine (1993)
- Johns Hopkins Bloomberg School of Public Health / Preventive Medicine (1997)
- Georgetown University / Internal Medicine (2001)
- National Institute of Allergy & Infectious Diseases NIH / Infectious Diseases (2004)
- American Board of Internal Medicine / Infectious Disease (2003, 2018)
Research & Publications
My research focuses on understanding the natural history of viral infections, particularly HIV and the hepatitis viruses, in both domestic and international settings. The ALIVE (AIDS Linked to the Intravenous Experience) study is a long-standing and productive cohort that characterizes the natural history of HIV infection among intravenous drug users in Baltimore, MD. Our research in ALIVE ranges from pathogenesis to clinical to behavioral. In particular, I focus on the non-AIDS outcomes of HIV including cancer, liver and lung diseases. I also work on related topics with international collaborators, primarily in Africa. The interaction of viral, environmental and genetic factors is an important determinant in progression of many viral diseases. My research employs genetic, proteomic, and other novel laboratory and imaging methods to help understand and identify individuals at greatest risk for clinically relevant outcomes from HIV, HBV and HCV infections. The long-term goal of this research is to translate these markers into targeted interventions to help reduce the burden from these infections.
Selected PublicationsView all on Pubmed
Linas BS, Genz A, Westergaard RP, Chang LW, Bollinger RC, Latkin C, Kirk GD. "Ecological momentary assessment of illicit drug use compared to biological and self-reported methods." JMIR Mhealth Uhealth. 2016 Mar 15;4(1):e27. doi: 10.2196/mhealth.4470.
An P, Penugonda S, Thorball CW, Bartha I, Goedert JJ, Donfield S, Buchbinder S, Binns-Roemer E, Kirk GD, Zhang W, Fellay J, Yu XF, Winkler CA. "Role of APOBEC3F gene variation in HIV-1 disease progression and pneumocystis pneumonia." PLoS Genet. 2016 Mar 4;12(3):e1005921. doi: 10.1371/journal.pgen.1005921. eCollection 2016 Mar.
Patel EU, Cox AL, Mehta SH, Boon D, Mullis CE, Astemborski J, Osburn WO, Quinn J, Redd AD, Kirk GD, Thomas DL, Quinn TC, Laeyendecker O. "Use of Hepatitis C Virus (HCV) immunoglobulin G antibody avidity as a biomarker to estimate the population-level incidence of HCV infection." J Infect Dis. 2016 Jan 14. pii: jiw005. [Epub ahead of print]
Robbins HA, Fennell CE, Gillison M, Xiao W, Guo Y, Wentz A, Kirk GD, Mehta SH, D'Souza G. "Prevalence of and risk factors for oral human papillomavirus infection among HIV-positive and HIV-negative people who inject drugs." PLoS One. 2015 Nov 24;10(11):e0143698. doi: 10.1371/journal.pone.0143698. eCollection 2015.
McLaren PJ, Coulonges C, Bartha I, Lenz TL, Deutsch AJ, Bashirova A, Buchbinder S, Carrington MN, Cossarizza A, Dalmau J, De Luca A, Goedert JJ, Gurdasani D, Haas DW, Herbeck JT, Johnson EO, Kirk GD, Lambotte O, Luo M, Mallal S, van Manen D, Martinez-Picado J, Meyer L, Miro JM, Mullins JI, Obel N, Poli G, Sandhu MS, Schuitemaker H, Shea PR, Theodorou I, Walker BD, Weintrob AC, Winkler CA, Wolinsky SM, Raychaudhuri S, Goldstein DB, Telenti A, de Bakker PI, Zagury JF, Fellay J. "Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load." Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):14658-63. doi: 10.1073/pnas.1514867112. Epub 2015 Nov 9.
Drummond MB, Kirk GD. HIV-associated lung disease: Recent insights and implications for the clinician. Lancet Respir Med, 2014; 2(7): 583-92. PMCID: PMC4111094
Linas BS, Latkin C, Westergaard RP, Chang LW, Bollinger RC, Genz A, Kirk GD. Capturing illicit drug use where and when it happens: an ecologic momentary assessment of the social, physical and activity environment of using versus craving illicit drugs. Addiction, 2014. (In Press)
Greene M, Covinsky K, Astemborski J, Piggott DA, Brown T, Leng S, Galai N, Mehta SH, Guralnik J, Patel KV, Kirk GD. The relationship of physical performance with HIV disease and mortality: A cohort study. AIDS; 2014. (In Press)
Linton SL, Jennings JJ, Latkin C, Kirk GD, Mehta SH. The association between neighborhood residential rehabilitation and injection drug use in Baltimore, Maryland, 2000-2011. Health & Place, 2014; 28C:142-149. PMID: 24840154
Kirk GD, Linas BS, Westergaard RP, Piggott D, Bollinger RC, Chang L, Genz A. The EXposure Assessment in Current Time (EXACT) Study: Implementation, feasibility and acceptability of real-time data collection in a community cohort of illicit drug users, AIDS Res Treat, 2013: 594671. PMCID: PMC3836292
Salter ML, Lau B, Mehta SH, Go VF, Leng S, Kirk GD. Correlates of elevated interleukin-6 and C-reactive protein in persons with or at high-risk for HCV and HIV infections. JAIDS, 2013; 64(5):488-95. PMCID: PMC3848037
Westergaard RP, Hess T, Astemborski J, Mehta SH, Kirk GD. Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS, 2013; 27(16): 2559-66. PMCID: PMC3795966
Popescu I, Drummond MB, Gama L, Merlo CA, Astemborski J, Brown RH, Wise RA, Clements JE, Kirk GD, McDyer JF. Activation-induced cell death drives profound lung CD4+ T cell depletion in HIV-associated chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2014. [Epub ahead of print] PMID: 25137293.
Drummond MB, Astemborski J, Lambert AA, Goldberg S, Stitzer ML, Merlo CA, Rand CS, Wise RA, Kirk GD. A randomized pilot study of contingency management and spirometric lung age for motivating smoking cessation among injection drug users. BMC Public Health, 2014; 28(14):761
Viswanathan S, Detels R, Mehta SH, Macatangay BJC, Kirk GD, Jacobson LP. Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy. AIDS Behavior; 2014. (In Press)
Kirk GD, Mehta SH, Astemborski J, Galai N, Washington J, Higgins Y, Balagopal A, Thomas DL. HIV, age, and the severity of hepatitis C virus-related liver disease. Ann Intern Med, 2013; 158(9): 658-666. PMCID: PMC3708651
Lambert A, Merlo CA, Kirk GD. HIV-associated lung malignancies. Clin Chest Med, 2013; 34(2): 255-272. PMCID: PMC3670780
Drummond MB, Astemborksi J, Marshall MM, Mehta SH, McDyer JF, Brown RH, Wise RA Merlo CA, Kirk GD. The effect of HIV infection on longitudinal lung function decline: A prospective cohort. AIDS, 2013; 27(8): 1303-1311. PMCID: PMC3953568
Piggott DA, Muzaale AD, Mehta SH, Brown TT, Leng SX, Kirk GD. Frailty, HIV infection, and mortality in an aging cohort of injection drug users. PLoS One, 2013; 8(1): e54910. PMCID: PMC3561408
Fischer WA, Drummond MB, Merlo CA, Thomas DL, Brown R, Mehta SH, Wise RA, Kirk GD. Hepatitis C virus infection is not an independent risk factor for obstructive lung disease. COPD, 2014; 11(1): 10-6. PMID: 23862666
Activities & Honors
- Elected Fellow, Infectious Diseases Society of America, 2013
- Elected Fellow, American College of Epidemiology, 2012
- Outstanding Teacher Award, Principles of Epidemiology, 2012
- Outstanding Teacher Award, Principles of Epidemiology, 2010
- Gustav J. Martin Innovative Fund for Research on HIV/AIDS Award, 2005
- Thomas and Carol McCann Innovative Fund for Asthma and Respiratory Disease Award, 2005
- Phi Beta Kappa, Johns Hopkins Bloomberg School of Public Health, 2003
- NIH Fellow’s Award for Research Excellence, 2002
- George McCracken Infectious Disease Fellow Award, American Society of Microbiology, 2002
- Visiting Scientist, International Agency for Research on Cancer, 1998
- Fellowship for Research Training in Cancer, International Agency for Research on Cancer, 1997
- Glaxo-Wellcome Resident Leadership Award for Outstanding Community Service, AMA, 1996
- Delta Omega National Public Health Honor Society, 1995
- American Cancer Society, Physician Training Award in Preventive Medicine, 1994 - 1997